Of the patients with recurrent EOC (n = 104),86.5%patients had a normal platelet count (mean 197,000 cells/μl) after primary therapy,and mean platelet counts at the diagnosis of recurrence were found to be increased to 227,000 cells/μl compared to that after primary therapy (P = 0.007, Fig. 2a).CA125 is a standard tumor marker followed in ovarian cancer to track the efficacy of primary therapy and in surveillance for recurrence. This evidence concerns the gene MUC16 and neoplasm.